纳洛酮联合依达拉奉治疗脑血管疾病的疗效及其机制研究

目的 探讨纳洛酮联合依达拉奉治疗脑血管疾病的疗效及其机制。方法 将180例缺血性脑血管疾病患者随机分为两组，每组各90例，对照组给予依达拉奉注射液30 mg静脉滴注，每日2次，研究组在对照组基础上给予盐酸纳洛酮注射液2 mg静脉滴注，每日2次。两组均连用14 d。分别在治疗前、治疗后检测血清丙二醛（MDA）、超氧化物岐化酶（SOD）浓度以及血液流变学指标。比较两组的临床疗效和不良反应。结果 治疗后，两组血清MDA浓度均较治疗前降低，SOD浓度均较治疗前升高，同组治疗前后比较差异有统计学意义（P<0.05）；且研究组MDA浓度明显低于对照组，SOD浓度明显高于对照组，组间比较差异有统计学意义（P<0.05）。研究组治疗后血液流变学指标改善情况明显优于对照组，差异有统计学意义（P<0.05）。研究组总有效率94.4%，明显高于对照组83.3%，差异有统计学意义（P<0.05）。两组均无明显不良反应。结论 纳洛酮联合依达拉奉治疗脑血管疾病能增进疗效，其机制可能与提高SOD，降低MDA，改善脑组织供血有关。

Edaravone combined with Naloxone in treatment of cerebral vascular disease and mechanism investigation

Objective To investigate the effect and mechanism of edaravone combined with naloxone in treatment of cerebral vascular disease. Methods 180 patients with ischemic cerebrovascular disease were randomly divided into two groups with 90cases in each group, and the control group were treated with Edaravone, and the study group were treated with Edaravone combined with Naloxone. The serum malondialdehyde (MDA), superoxide dismutase (SOD) concentration and blood rheology indexs before and 14d after treatment of were detected, and clinical efficacy and adverse reactions were compared between the two groups. Results The serum MDA concentration 14d after treatment of the study group was significantly lower than that of the control group (P < 0.05), and the SOD concentration was significantly higher than that of control group (P < 0.05). The blood rheology indexs 14 d after treatment of the study group were significantly improved than those of the control group (P < 0.05). The total effective rate of the study group with 94.4% was significantly higher than that of the control group with 83.4% (P < 0.05). There were no obvious adverse reaction in the two groups. Conclusions Edaravone combined with naloxone in treatment of cerebral vascular disease can enhance the therapeutic effect, and the mechanism may be associated with increased SOD, reduced MDA, and improved blood supply to the brain.